Skip to Content

Vabomere FDA Approval History

FDA Approved: Yes (First approved August 29, 2017)
Brand name: Vabomere
Generic name: meropenem and vaborbactam
Dosage form: Injection
Previous Name: Carbavance
Company: The Medicines Company
Treatment for: Urinary Tract Infection

Vabomere (meropenem and vaborbactam) is a carbapenem and beta-lactamase inhibitor combination for the treatment of complicated urinary tract infections (cUTIs).

Development Timeline for Vabomere

Aug 29, 2017Approval FDA Approves Vabomere (meropenem and vaborbactam) for Complicated Urinary Tract Infections
Feb 21, 2017The Medicines Company Announces FDA Filing Acceptance of New Drug Application for Intravenous Antibiotic Carbavance (meropenem-vaborbactam)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.